Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Melanoma (Skin), Metastatic Cancer
Interventions: aldesleukin, histamine dihydrochloride; Biological · Drug
Lead sponsor: Maxim Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 11
States / cities: Santa Monica, California • Aurora, Colorado • Tampa, Florida + 7 more

Conditions: Atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Hemolytic Anemia
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Melanoma
Interventions: DNX-2401; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Adjuvant Radiotherapy; Radiation
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2008
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Erythema, Edema
Interventions: Trojan "Chameleon" Personal Lubricant; Device
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Atopic Dermatitis
Interventions: Combination of pimecrolimus and fluticasone, pimecrolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Houston, Texas

Conditions: Melanoma
Interventions: Dabrafenib, Trametinib, Trametinib placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Acthar; Drug
Lead sponsor: Veena Ranganath, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Active Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 62
States / cities: Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more

Conditions: Herpes Simplex Labialis
Interventions: Zicam (Ionic zinc), placebo; Drug
Lead sponsor: Integrative Medicine Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Tempe, Arizona • Santa Fe, New Mexico • New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 7,933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ridgefield, Connecticut

Conditions: Psoriasis
Interventions: Brodalumab; Biological
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: San Diego, California • Miami, Florida • Henderson, Nevada + 1 more

Conditions: Psoriasis
Interventions: CTA018 cream; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more

Conditions: Androgenic Alopecia
Interventions: Tattoo machine; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Triple Negative Breast Cancer
Interventions: Lenvatinib, Pembrolizumab; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Purpura, Thrombotic Thrombocytopenic, TTP
Interventions: N-Acetylcysteine; Drug
Lead sponsor: Bloodworks; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions: zoledronic acid; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 503
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more

Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions: Not listed
Lead sponsor: Edimer Pharmaceuticals; Industry
Eligibility: Up to 36 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri

Conditions: Melanoma
Interventions: High dose bolus interleukin-2 (HD IL2); Drug
Lead sponsor: Ahmad Tarhini; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions: Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
Interventions: Active Breathing Coordinator; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasm
Interventions: Sagopilone (ZK 219477); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 21
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 18 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib + an aromatase inhibitor, Aromatase inhibitor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

The Role of Microparticles as a Biomarker

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast

A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects

Combination Therapy for Atopic Dermatitis

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Zinc for the Treatment of Herpes Simplex Labialis (HSL)

Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

HSCT for High Risk Inherited Inborn Errors

Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors